For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260217:nRSQ3818Ta&default-theme=true
RNS Number : 3818T Victrex PLC 17 February 2026
17 February 2026
Victrex plc
Director/PDMR Shareholding
On 16 February 2026, Dr James Routh, Chief Executive Officer of Victrex plc
(Victrex), sold sufficient shares in Victrex to cover the associated income
tax and NI liabilities arising from the award of 13,035 Deferred Bonus Buyout
Shares on 12 February 2026 and retained the balance of 6,886 shares. He also
exercised 47,031 nil cost share options granted under Parts 1 and 2 of the
2023 LTIP Buy-Out Award granted on 12 February 2026 and sold sufficient shares
to cover the associated income tax and NI liabilities, retaining the balance
of 24,849 shares, at a price of £7.03 per ordinary share.
As a result of these transactions, Dr. Routh holds 36,255 ordinary shares in
Victrex including 4,520 shares purchased on 5 December 2025, prior to becoming
Chief Executive Officer on 1 January 2026.
The FCA notification in respect of the above made in accordance with the
requirements of the UK Market Abuse Regulation, is appended below.
Enquiries:
Andrew Hanson, Director of Investor Relations, Corporate Communications &
ESG +44 (0) 7809 595831
About Victrex:
Victrex is an innovative world leader in high performance polymer solutions,
focused on the strategic markets of Automotive, Aerospace, Energy &
Industrial, Electronics and Medical. Every day, millions of people rely on
products or applications which contain our sustainable materials, from
smartphones, aircraft and cars to energy operations and medical devices. With
over 40 years' experience, we are moving beyond the polymer into semi-finished
and finished products which shape future performance for our customers and our
markets, enable environmental and societal benefit for our customers and drive
value for our shareholders. Find out more at www.victrexplc.com
(http://www.victrexplc.com)
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them.
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Dr James Routh
2 Reason for the notification
a) Position/status Chief Executive Officer
b) Initial notification /Amendment Initial Notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Victrex plc
b) LEI 213800UYNPHAUNHPXL67
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares of 1p each-
Identification code GB0009292243
b) Nature of the transaction 1. Sale of sufficient Deferred Bonus Buyout Shares awarded 12 February
2026 to cover costs. Retained balance of 6,886 shares
2. Exercise of 47,031 nil cost share options granted under Parts 1 and 2
of the 2023 LTIP Buy-Out Award granted 12 February 2026 and sale of sufficient
shares to cover costs. Retained balance of 24,849.
c) Price(s) and volume(s)
Price(s) Volume(s)
£ 7.03 28,331
d) Aggregated information n/a single transaction
- Aggregated volume
- Price
e) Date of the transaction 2026-02-16
f) Place of the transaction London Stock Exchange
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHGZGMZKNDGVZM
Copyright 2019 Regulatory News Service, all rights reserved